StockIQpro
NASDAQ:TECX

Tectonic Therapeutic, Inc.

Track all markets on TradingView
Track all markets on TradingView

Tectonic Therapeutic, Inc. reported net income of −$74.2M in fiscal 2025. Free cash flow was −$60.3M, and the diluted share count rose 115.8%.Summary generated from Tectonic Therapeutic, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−37.8%
Debt / equityn/a
Free cash flow−$60.3M
FCF marginn/a
Share count change+115.8%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−119−105−45−58−84
Net income−119−106−43−58−74
Free cash flow−100−97−41−59−60

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)